滚动资讯
FierceBiotechFDA rejects Replimune’s melanoma prospect for second timeEndpoints NewsPlan for remade ACIP panel adds focus on vaccine safety, matching Kennedy’s pushEndpoints NewsBayer pharma executive predicts US-Europe price spreads will narrowBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-April 9, 2026Endpoints NewsFDA rejects Replimune cancer therapy, saying company didn't resolve trial doubtsBioPharma DiveFDA again spurns Replimune melanoma drugIlluminaWill Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? - Yahoo FinanceBioWorldIn the clinic for April 10, 2026BioWorldOther news to note for April 10, 2026BioWorldRegulatory actions for April 10, 2026Endpoints NewsChina biotech’s CRISPR therapy suggests US drugmakers will face competition
FierceBiotech 2026年4月10日

FDA rejects Replimune’s melanoma prospect for second time

FDA rejects Replimune’s melanoma prospect for second time

原文
暂时没有全文，请查看原始来源。

目录

59 全部